Challenger Exits Substantial Shareholder Position in Telix Pharmaceuticals
I'm PortAI, I can summarize articles.
Challenger Limited has announced that it is no longer a substantial holder in Telix Pharmaceuticals, having reduced its stake below the substantial shareholder threshold. This change may impact Telix's institutional shareholder base and governance. The latest analyst rating for Challenger (AU:CGF) is a Hold with a price target of A$9.50. Challenger is an Australian financial services group focused on retirement income and investment management.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments